Bernard is a Managing Director in Healthcare Investment Banking at Canaccord Genuity (Australia). He has advised senior management teams and boards for over 15 years on a range of financial and strategic matters, successfully executing over 100 transactions, including US$10 billion in financings and US$80 billion in M&A and advisory activities. Bernard returned to Australia after spending 17 years in New York, US. Prior to joining the Australian team in 2023, Bernard was a Managing Director in Healthcare Investment Banking at Canaccord Genuity (US) for over 5 years and an Executive Director in Healthcare Investment Banking at Oppenheimer & Co (US) for over 7 years. Bernard has a PhD from the University of Adelaide and an MBA from Stern School of Business at New York University.
Selected Transactions
-
US$50m
Galmed
Co-Agent (ATM Offering)
-
US$138m
Adicet Bio, Inc.
Co-Manager (CMPO)
-
US$145m
Sigilon Therapeutics
Bookrunner (IPO)
-
US$240m
Olema Pharmaceuticals, Inc.
Bookrunner (IPO)
-
US$512m
BioNTech SE
Lead Manager (Follow-On)
-
US$633m
Allogene Therapeutics, Inc.
Co-Manager (Follow-On)
-
N/a
Cortexyme, Inc.
Financial Advisor (Private Placement)
-
US$231m
Black Diamond Therapeutics, Inc.
Lead Manager (IPO)
-
US$86m
Forty Seven, Inc.
Lead Manager (Follow-on)